Histone deacetylase inhibitors have attracted considerable attention because of their ability to overcome the differentiation block in leukemic blasts, an effect achieved either alone or in combination with differentiating agents, such as all-trans retinoic acid. We have previously reported favorable effects of the potent histone deacetylase inhibitor valproic acid in combination with all-trans retinoic acid in patients with advanced acute myeloid leukemia leading to blast cell reduction and improvement of hemoglobin. These effects were accompanied by hypergranulocytosis most likely due to an enhancement of nonleukemic myelopoiesis and the suppression of malignant hematopoiesis rather than enforced differentiation of the leukemic cells. These data prompted us to investigate the effect of valproic acid on normal hematopoietic stem cells (HSC). Here we show that valproic acid increases both proliferation and self-renewal of HSC. It accelerates cell cycle progression of HSC accompanied by a down-regulation of p21 cip-1/waf-1 . Furthermore, valproic acid inhibits GSK3B by phosphorylation on Ser9 accompanied by an activation of the Wnt signaling pathway as well as by an up-regulation of HoxB4, a target gene of Wnt signaling. Both are known to directly stimulate the proliferation of HSC and to expand the HSC pool. In summary, we here show that valproic acid, known to induce differentiation or apoptosis in leukemic blasts, stimulates the proliferation of normal HSC, an effect with a potential effect on its future role in the treatment of acute myeloid leukemia. (Cancer Res 2005; 65(7): 2537-41) 
Introduction
Acute myeloid leukemia (AML) is characterized by a differentiation block leading to the accumulation of immature blasts in the bone marrow. The vast majority of AML-patients are over 60 years old and experience a median survival below 1 year even if treated with intensive chemotherapy (1) . Therefore, there is the necessity to develop alternative treatment strategies, such as a differentiation-inducing therapy employing histone deacetylase inhibitors (HDI). HDI have been shown to promote differentiation either alone or in combination with differentiating agents such as all-trans retinoic acid (t-RA; refs. 2, 3). Valproic acid (4), a potent HDI which has been safely used for over two decades in the therapy of epilepsy and bipolar disorders, is now under clinical evaluation (5) . In a current clinical study we are evaluating a valproic acid/t-RA combination therapy on patients suffering from advanced myeloid malignancies (6) . Patients responding to this therapy frequently developed constant or increased bone marrow cellularity despite a remarkable blast cell reduction and peripheral hypergranulocytosis (>100,000 cells/L; ref. 6 ). In one patient, it was possible to distinguish malignant from normal hematopoiesis by the presence of the isochromosome (17)(q10) in the leukemic blasts. The analysis revealed that whereas the CD34 + progenitor cells contained residual i(17)(q10), all granulocytes had a normal karyotype, suggesting dominance of normal hematopoiesis over the malignant clone. 1 Based on the hypothesis that this clinical picture might be related to a still unknown effect of valproic acid, we here investigated its activity on hematopoietic stem cells (HSC) with respect to differentiation, proliferation as well as to self-renewal.
Materials and Methods
Enrichment of human and murine hematopoietic stem cells. Bone marrow was obtained from healthy donors and umbilical cord blood was collected with informed consent of the donors or mothers, respectively. Isolation of mononuclear cells, CD34 + cell selection, and isolation of Sca1 + /lin À HSC from C57BL/6J (Ly5.2) female mice or congenic C57BL/6.SJL-Ly5.1 mice (Charles River, Sulzfeld, Germany) were done as previously described (7, 8) .
Culture and colony assay of CD34 + + + hematopoietic stem cells. CD34 + cells were cultured and colony formation of CD34 + HSC was assessed as previously described (7) . Cells were harvested after 7 days, counted, and assayed for CD34 and CD14 expression as previously described (7) .
Replating efficiency and differentiation of Sca + + + /lin À À À hematopoietic stem cells. Colony formation, replating efficiency, and differentiation were assessed as recently described (8) . Western blotting. Western blotting was done according to widely used protocols using the following antibodies: anti-p21 cip-1/waf-1 , anti-GSK3h, anti-Ser9-phospho GSK3h, anti-Akt, anti-phospho Akt, anti-h-catenin, anti-phospho h-catenin (all from Santa Cruz Biotech, Santa Cruz, CA), anti-HoxB4 (DSHB, University of Iowa, Iowa City, IA), and anti-h-tubulin (Calbiochem/Merck, Darmstadt, Germany). Blocking was done in TBS containing 0.1% Tween 20 (TBS-T) with 5% low-fat dry milk; washing was carried out in TBS-T. Antibody incubations were done in either 0.5% low-fat dry milk or TBS-T.
Real-time PCR. Total RNA and first strand DNA were obtained according to widely accepted protocols. The TaqMan PCR was conducted in duplicates following standard protocols using the ABI PRISM 7700 (PE Biosystems, Weiterstadt, Germany). HoxB4 was amplified with the two primers HoxB4fwd (CGT CAG GTA GCG GTT GTA GTG A) and HoxB4rev (CGT CAG GTA GCG GTT GTA GTG A) and the specific probe HoxB4-FAM (TGA GCA CGG TAA ACC CCA ATT ACG CC) labeled with FAM at the 5V end and TAMRA at the 3V end. Normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was done for each sample. CT values were exported into a Microsoft Excel worksheet for calculation of fold changes according to the y-y CT method.
Results
Valproic acid increases the proliferation of human CD34 + + hematopoietic stem cells. To determine the effects of valproic acid on HSC, their proliferation and differentiation potential was analyzed in human CD34
+ HSC in the presence of increasing doses of valproic acid (30-150 Ag/mL). Valproic acid prevented differentiation of bone marrow CD34 + cells in a dose-dependent manner as revealed by the increase of CD34 + cells and the concomitant decrease of monocytic CD14 + cells in a 7-day liquid culture (Fig. 1A) .
Even on higher differentiation pressure in a semisolid medium supplemented with FCS and granulocyte colony-stimulating factor (G-CSF), 150 Ag/mL of valproic acid increased the percentage of CD34 + cells from 0.5% to more than 21% (Fig. 1B) . In umbilical cord blood CD34 + cells harvested after 10 days of culture in semisolid medium, valproic acid augmented the number of CD34 + cells in a dose-dependent manner to more than 1 log with respect to untreated cells (Fig. 1C) .
These data clearly indicate that valproic acid does not induce differentiation, but proliferation in HSC.
Treatment with valproic acid increases the replating efficiency as well as the self-renewal potential of murine hematopoietic stem cells. To compare the effect of valproic acid on HSC with the known expanding effect of t-RA on murine HSC (10), we extended our investigations to murine Sca1
Thus, we compared the effect of valproic acid (150 Ag/mL) on the replating efficiency of Sca1 + /lin À HSC in semisolid medium with that of t-RA (1 Amol/L). Valproic acid not only enhanced the number of colony-forming units (CFU; Fig. 2A ) but, in contrast to the controls and t-RA, valproic acid also allowed a second plating with a constant number of CFU ( Fig. 2A) . Upon exposure to valproic acid, it was possible to replate Sca1 + /lin À HSC up to four times (data not shown). The valproic acid-treated cells did not differentiate as shown by the high levels of the stem cell markers Sca1 and c-Kit (Fig. 2B ).
To investigate whether the effect of valproic acid on HSC is related to an increase of their potential for self-renewal, we inoculated HSC treated for 2 days with t-RA or with valproic acid into lethally irradiated recipient mice. At day 12 we analyzed the spleen colony-forming units (CFU-S). Valproic acid-treated HSC gave origin to a higher number of CFU-S as compared with control and t-RA-treated HSC as revealed by the differences in the spleen size (Fig. 2C) . Exposure to valproic acid led to a higher percentage of c-Kit-and Sca1-expressing cells in the CFU-S as compared with controls (Fig. 2D) . No difference was seen regarding CD3q, B220, or Ter119 expression between the different conditions (data not shown), indicating that the treatment did not influence the multipotency of the cells (11) .
To confirm the effect of valproic acid on the long-term HSC, a competitive repopulation assay on six mice per group was done and analyzed at 12 weeks after the transplantation. As compared with the untreated controls (8%), exposure to valproic acid increased the long-term potential of HSC (18%) even to a lower extent than t-RA (23%; Fig. 2E ).
In summary, these data suggest that the exposure to valproic acid not only induces proliferation of murine HSC but also increases their self-renewal potential.
Valproic acid accelerates cell cycle progression of hematopoietic stem cells and down-regulates p21 cip-1/waf-1 . Next we investigated the effect of valproic acid on the cell cycle progression of the HSC. The cell cycle analysis was assessed using Sca1 + /lin À HSC cultured for 7 days in semisolid medium in the presence or absence of 150 Ag/mL valproic acid. In contrast to t-RA, valproic acid increased the percentage of the cells in S phase (23% and 38%, respectively) as compared with untreated control cells (20%) with a concomitant reduction of cells in G 1 phase (Fig. 3A) . Next we examined the effect of valproic acid on the expression of the CDK inhibitor p21 cip-1/waf-1 in Sca1 + /lin À HSC cultured in the semisolid medium for 7 days as well as in bone marrow CD34 + cells cultured for 2 days by Western blotting. In contrast to t-RA, valproic acid reduced the expression level of p21 cip-1/waf-1 , an effect still notable at day 7 in murine HSC (Fig. 2B ) and at day 2 in CD34 + cells (Fig. 2C) .
Taken together, these data indicate that valproic acid accelerates cell cycle progression of HSC.
Valproic acid activates GSK3B-dependent signaling pathways and up-regulates HoxB4 in hematopoietic stem cells. GSK3h becomes inhibited by phosphorylation on Ser9 on exposure Research. (12) . To disclose the mechanisms by which valproic acid induces proliferation of HSC, we studied the effects of valproic acid on GSK3h in HSC as well as in KG-1 cells cultured under conditions under which about 80% of the cell population were CD34 + /CD38 À (data not shown).
Valproic acid induced a strong modification of GSK3h in bone marrow CD34 + cells at 48 hours (Fig. 4A) as well as in the murine Sca1 + /lin À at day 7 of exposure ( Fig. 4B) . In fact, GSK3h
was Ser9-phosphorylated in HSC on exposure to valproic acid but not to t-RA (Fig. 4B) , indicating an inhibition of GSK3h. This effect was also seen in KG-1 cells (Fig. 4C) . GSK3h is known to be Ser9-phosphorylated by activated Akt (13) . In CD34 + Akt was activated after 48 hours, whereas in Sca1 + / lin À no activated Akt was seen at day 7 of exposure, most likely due to the late time point of analysis as shown in KG-1 cells in which activated Akt returned to control levels after 96 hours (Fig. 4F) . Ser9-phosphorylated GSK3h stabilizes h-catenin. Given the fact that in both CD34 + and Sca1 + /lin À endogenous h-catenin was hardly detectable using a variety of antibodies (Fig. 4E and data not shown), we confirmed the up-regulation of h-catenin on exposure to valproic acid in KG-1 cells, which are >80% CD34 + / CD38 À (Fig. 4F ).
HoxB4, a key factor in the regulation of the self-renewal and the proliferation of HSC, is a target gene of h-catenin (14) . The expression level of HoxB4 in human bone marrow CD34 + cells was assessed by quantitative real-time PCR at 48 hours of exposure to valproic acid. Valproic acid increased the number of HoxB4 transcripts about 3.8 times in these cells (Fig. 4G) . In Sca1 + /lin À murine HSC the expression level of HoxB4 was measured by Western blotting at day 7 of treatment. In contrast to t-RA, which seemed to reduce the amount of HoxB4, valproic acid increased the expression of HoxB4 (Fig. 4H) . These data indicate that valproic acid influences signaling pathways relevant for both self-renewal and proliferation of HSC by the inhibition of GSK3h.
Discussion
Valproic acid is one of the most promising HDI, raising the hope that a successful differentiation therapy of AML might be feasible. Here we show that valproic acid has unexpected effects on HSC requesting reconsideration of its role in the treatment of AML.
In contrast to recent reports which show that valproic acid induces differentiation in leukemic blasts (3), valproic acid blocks differentiation of normal HSC as revealed by the fact that it increases the fraction of HSC rather than differentiated cells. Furthermore, valproic acid increased the replating efficiency of murine HSC. An asymmetrical induction of apoptosis in the HSC population by valproic acid was excluded by the evidence that valproic acid accelerates the cycle progression of HSC accompanied by a down-regulation of p21 cip-1/waf-1 . This is in contrast to the effect of valproic acid and other HDI, such as Laq824, which increase p21 cip-1/waf-1 expression in cell line models of acute leukemia followed by differentiation or apoptosis (15, 16) . Thus, valproic acid has differential effects on stem cells as compared with blast cells. Laq824 and CG1521, two potent hydroxamic acid-derived HDI, which induce differentiation and/or apoptosis in leukemia cell lines, share the properties of valproic acid on HSC (ref. 17 and data not shown). There is a relationship between the differentiation level and the response to HDI, meaning that very immature cells respond to HDI with a down-regulation of p21 cip-1/waf-1 and cell cycle progression, whereas at a more advanced differentiation stage, cells respond to valproic acid and Laq824 with a down-regulation of p21 cip-1/waf-1 and differentiation or apoptosis (15, 16) . One can hypothesize that valproic acid increases self-renewal of HSC by (a) a ''transcriptional reprogramming'' of these cells through its capacity to induce histone acetylation as well as DNA demethylation in a dose-dependent manner (18) , or (b) by the inhibition of GSK3h. The Ser9 phosphorylation of GSK3h reduces its kinase activity on h-catenin (13) enabling it to transcriptionally activate Wnt target genes (19) . The activation of the Wnt signaling pathway on valproic acid is confirmed also by the fact that HoxB4, a target gene of the Wnt signaling pathway in HSC (14) , is upregulated on exposure to valproic acid. Both HoxB4 and Wnt signaling are crucial for the self-renewal potential of HSC (14) . In fact, similarly to t-RA (9), valproic acid increases self-renewal of HSC as shown in the CFU-S as well as in the competitive repopulation assays.
The increase in the proliferation and self-renewal potential of HSC by valproic acid may have important therapeutic consequences. The valproic acid-induced entry of quiescent hematopoietic and leukemic stem cells into the cell cycle could render them more susceptible to conventional chemotherapy, resulting either in a prolonged aplasia due to a higher efficiency of the therapy or in a shortened aplasia owing to the enforced proliferation of the normal hematopoiesis. Our recent clinical data indicate that the exposure to valproic acid increases the response to chemotherapeutic agents (6) .
The here presented data suggest to redirect the role of HDI from a desired differentiation inducer in a coadjuvant factor for increasing the response to conventional therapy.
